After 2 or more systemic therapies in mRCC treatment… Power To Go Further

mPFS: 5.6 months with FOTIVDA vs 3.9 months with sorafenib (HR=0.73 [95% CI: 0.56, 0.95], P=0.02)¹

After 2 or more systemic therapies in mRCC treatment… Power To Go Further

mPFS: 5.6 months with FOTIVDA vs 3.9 months with sorafenib (HR=0.73 [95% CI: 0.56, 0.95], P=0.02)¹

Tivozanib (FOTIVDA) is an NCCN recommended option for relapsed or stage IV ccRCC following ≥2 prior systemic therapies, including IO²

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

FOTIVDA is the first and only VEGFR TKI studied in rrRCC after 2 or more systemic therapies, including IO.

Find out what FOTIVDA can mean for your patients.

View PFS

References: 1. Rini BI, Pak SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95-104. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Kidney Cancer V.2.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 11, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.